|1.17|| -0.05 / -4.10%|
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress. It also offers drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
|Carl Spana||President, Chief Executive Officer & Director|
|Stephen T. Wills||COO, CFO, Secretary, Treasurer & Executive VP|
|Johna Lucas||Chief Medical Officer|